A recent study in KRAS mutated NSCLC patients had also shown that KRAS mutation presence or dynamic change in post treatment plasma was significantly associated with increased probability of experiencing progressive disease, and PFS and OS [25]. Here, KRAS is linked to non-small cell lung carcinoma.